| 6.88 -0.02 (-0.29%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.71 | 1-year : | 9.78 |
| Resists | First : | 7.46 | Second : | 8.38 |
| Pivot price | 7.21 |
|||
| Supports | First : | 5.98 | Second : | 4.97 |
| MAs | MA(5) : | 6.88 |
MA(20) : | 7.27 |
| MA(100) : | 9.74 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 19.5 |
D(3) : | 15.1 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 20.12 | Low : | 5.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RNAC ] has closed above bottom band by 21.6%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.1 - 7.13 | 7.13 - 7.17 |
| Low: | 6.7 - 6.75 | 6.75 - 6.8 |
| Close: | 6.8 - 6.88 | 6.88 - 6.95 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Fri, 05 Dec 2025
Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation - Yahoo Finance
Mon, 17 Nov 2025
Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis (NASDAQ:RNAC) - Seeking Alpha
Fri, 14 Nov 2025
BTIG Maintains Cartesian Therapeutics (RNAC) Buy Recommendation - Nasdaq
Thu, 13 Nov 2025
Cartesian (NASDAQ: RNAC) posts 100% LLDAS in SLE; expands Descartes-08 into myositis - Stock Titan
Tue, 11 Nov 2025
Recent 11% pullback would hurt Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders - simplywall.st
Thu, 06 Nov 2025
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 9.41e+006 (%) |
| Held by Institutions | 59.7 (%) |
| Shares Short | 2,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.108e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 660.6 % |
| Return on Equity (ttm) | -12.7 % |
| Qtrly Rev. Growth | 1.09e+006 % |
| Gross Profit (p.s.) | 43.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.32718e+008 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.95 |
| Dividend | 0 |
| Forward Dividend | 2.03e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|